Amryt reports higher Q1 revenues and deal with Chiasma
Amryt Pharma has agreed to buy US firm Chiasma in an all stock deal that values the US firm at $330m. The news came as it reported that its first quarter revenues rose by 8.7%.
Business
• 05 May 21
